ISSUE 1402
| Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue. |
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H1-antihistamine and a corticosteroid.
DRUGS FOR ALLERGIC RHINITIS — Mild to moderate allergic rhinitis is usually treated with an oral second-generation H1-antihistamine, such as loratadine (Claritin, and generics) or fexofenadine (Allegra, and generics).1 Intranasal H1-antihistamines such as azelastine and olopatadine (Patanase) are alternatives; their clinical efficacy appears
... more1. FE Simons and KJ Simons. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011; 128:1139.
2. Olopatadine (Patanase) nasal spray for allergic rhinitis. Med Lett Drugs Ther 2008; 50:51.
3. Azelastine (Astepro) nasal spray for allergic rhinitis. Med Lett Drugs Ther 2009; 51:29.
4. Drugs for allergic disorders. Treat Guidel Med Lett 2010; 8:9.
Would you like to read the rest of this issue? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
